• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃及两家三级医院复杂腹腔内感染病原菌的分布及耐药性

Distribution and Antimicrobial Resistance of Complicated Intraabdominal Infection Pathogens in Two Tertiary Hospitals in Egypt.

机构信息

Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.

Department of Microbiology and Immunology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.

出版信息

Surg Infect (Larchmt). 2024 Nov;25(9):682-690. doi: 10.1089/sur.2023.375. Epub 2024 Aug 22.

DOI:10.1089/sur.2023.375
PMID:39172656
Abstract

Management of complicated intraabdominal infections (cIAIs) requires containment of the source and appropriate initial antimicrobial therapy. Identifying the local data is important to guide the empirical selection of antimicrobial therapy. In this study, we aimed to describe the pathogen distribution and antimicrobial resistance of cIAI. In two major tertiary care hospitals in Egypt, we enrolled patients who met the case definition of cIAI from October 2022 to September 2023. Blood cultures were performed using the BACTAlert system (BioMerieux, Marcy l'Etoile, France). A culture of aspirated fluid, resected material, or debridement of the infection site was performed. Identification of pathogens and antimicrobial susceptibility testing were conducted by the VITEK-2 system (BioMerieux, Marcy l'Etoile, France). Gram-negative resistance genes were identified by PCR and confirmed by whole bacterial genome sequencing using the Nextera XT DNA Library Preparation Kit and sequencing with the MiSeq Reagent Kit 600 v3 (Illumina, USA) on the Illumina MiSeq. We enrolled 423 patients, 275 (65.01%) males. The median age was 61.35 (range 25-72 years). We studied 452 recovered bacterial isolates. Gram-negative bacteria were the vast majority, dominated by followed by and (33.6%, 30.5%, 13.7%, 13%, and 5.4%, respectively). High rates of resistance were detected to third- and fourth-generation cephalosporins and fluoroquinolones. No resistance was detected to colistin. Resistance to amikacin and tigecycline was low among all isolates. Resistance to meropenem and ceftazidime/avibactam was moderate. ESBL genes were common in and . CTX-M15 gene was the most frequent. Among and were the most prevalent carbapenemase genes. isolates harbored a wide variety of carbapenemase genes (OXA, NDM, VIM, SIM, GIM, SPM, IMP, AIM), dominated by metallo-beta-lactamases. In 20.6% of isolates, we identified two or more resistance genes. High resistance rates were detected to third- and fourth-generation cephalosporins and fluoroquinolones. Amikacin and tigecyclines were the most active antimicrobials. Our data call for urgent implementation of antimicrobial stewardship programs and reinforcement of infection control.

摘要

复杂性腹腔内感染(cIAI)的管理需要控制感染源和适当的初始抗菌治疗。确定当地数据对于指导经验性选择抗菌治疗非常重要。在这项研究中,我们旨在描述 cIAI 的病原体分布和抗菌药物耐药性。在埃及的两家主要三级保健医院,我们招募了 2022 年 10 月至 2023 年 9 月符合 cIAI 病例定义的患者。使用 BACTAlert 系统(法国马西-莱托伊尔的生物梅里埃)进行血培养。采集抽吸液、切除物或感染部位清创的培养物。通过 VITEK-2 系统(法国马西-莱托伊尔的生物梅里埃)进行病原体鉴定和药敏试验。通过 PCR 鉴定革兰氏阴性耐药基因,并通过使用 Nextera XT DNA 文库制备试剂盒对整个细菌基因组进行测序和使用 Illumina MiSeq 试剂试剂盒 600 v3(Illumina,美国)在 Illumina MiSeq 上进行测序进行确认。我们共招募了 423 名患者,其中 275 名(65.01%)为男性。中位年龄为 61.35 岁(范围 25-72 岁)。我们研究了 452 株分离的细菌。革兰氏阴性菌占绝大多数,其中 、 和 (33.6%、30.5%、13.7%、13%和 5.4%)分别占主导地位。第三代和第四代头孢菌素和氟喹诺酮类药物的耐药率很高。未检测到对粘菌素的耐药性。所有分离株对阿米卡星和替加环素的耐药率均较低。美罗培南和头孢他啶/阿维巴坦的耐药率为中度。ESBL 基因在 和 中很常见。CTX-M15 基因是最常见的。在 和 中,碳青霉烯酶基因最常见。 分离株携带多种碳青霉烯酶基因(OXA、NDM、VIM、SIM、GIM、SPM、IMP、AIM),以金属β-内酰胺酶为主。在 20.6%的分离株中,我们鉴定出两种或两种以上的耐药基因。第三代和第四代头孢菌素和氟喹诺酮类药物的耐药率很高。阿米卡星和替加环素是最有效的抗菌药物。我们的数据表明,急需实施抗菌药物管理计划并加强感染控制。

相似文献

1
Distribution and Antimicrobial Resistance of Complicated Intraabdominal Infection Pathogens in Two Tertiary Hospitals in Egypt.埃及两家三级医院复杂腹腔内感染病原菌的分布及耐药性
Surg Infect (Larchmt). 2024 Nov;25(9):682-690. doi: 10.1089/sur.2023.375. Epub 2024 Aug 22.
2
Molecular characterization of multidrug-resistant Gram-negative pathogens in three tertiary hospitals in Cairo, Egypt.埃及开罗三家三级医院中耐多药革兰氏阴性病原体的分子特征分析。
Eur J Clin Microbiol Infect Dis. 2020 May;39(5):987-992. doi: 10.1007/s10096-020-03812-z. Epub 2020 Jan 17.
3
In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).临床呼吸道分离株对头孢他啶-阿维巴坦及对照药物的体外抗菌敏感性(2016 - 2018年)
BMC Infect Dis. 2021 Jun 23;21(1):600. doi: 10.1186/s12879-021-06153-0.
4
Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets.从参加头孢他啶-阿维巴坦治疗复杂性腹腔内感染3期试验的患者中分离出的需氧革兰氏阴性病原体的分子β-内酰胺酶特征,并针对敏感和耐药亚组分析疗效。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02447-16. Print 2017 Jun.
5
[In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].头孢他啶-阿维巴坦与黏菌素对耐碳青霉烯类肺炎克雷伯菌临床分离株的体外活性
Mikrobiyol Bul. 2022 Apr;56(2):218-229. doi: 10.5578/mb.20229803.
6
Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).监测在SMART研究(西班牙,2016年和2017年)期间分离出的、与腹腔内感染及泌尿道感染相关的革兰氏阴性菌的药敏情况。
Rev Esp Quimioter. 2019 Apr;32(2):145-155. Epub 2019 Feb 13.
7
Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.2006 至 2010 年间,台湾 5 家持续参与监测抗菌药物耐药性趋势(SMART)研究的医疗中心的复杂腹腔内感染患者分离病原菌的药敏结果。
Int J Antimicrob Agents. 2012 Jun;40 Suppl:S29-36. doi: 10.1016/S0924-8579(12)70007-9.
8
Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).头孢洛扎他唑巴坦对西班牙监测抗菌药物耐药性趋势研究(SMART)项目(2016-2018 年)期间分离的肠杆菌科和铜绿假单胞菌的抗菌活性。
Rev Esp Quimioter. 2021 Jun;34(3):228-237. doi: 10.37201/req/019.2021. Epub 2021 Mar 1.
9
In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).亚太地区 INFORM 项目(2015-2017 年)收集的革兰氏阴性细菌分离株的头孢他啶-阿维巴坦和对照药物的体外活性。
Ann Clin Microbiol Antimicrob. 2020 Apr 1;19(1):14. doi: 10.1186/s12941-020-00355-1.
10
Prevalence and characterization of antimicrobial resistance among gram-negative bacteria isolated from febrile hospitalized patients in central Ethiopia.埃塞俄比亚中部发热住院患者分离的革兰氏阴性菌的抗菌药物耐药性的流行情况及特征。
Antimicrob Resist Infect Control. 2022 Jan 15;11(1):8. doi: 10.1186/s13756-022-01053-7.

引用本文的文献

1
Comparison of the efficacy of cefoperazone-sulbactam and other cephalosporins in the treatment of infections: A systematic review and meta-analysis.头孢哌酮-舒巴坦与其他头孢菌素治疗感染的疗效比较:一项系统评价与荟萃分析。
Medicine (Baltimore). 2025 Apr 25;104(17):e42182. doi: 10.1097/MD.0000000000042182.